Posting Adverse Event Report Data Associated With Conventional Foods, Dietary Supplements, and Cosmetics on the Internet; Availability, 88244 [2016-29277]
Download as PDF
88244
Federal Register / Vol. 81, No. 235 / Wednesday, December 7, 2016 / Notices
(B) The Flores Settlement Agreement,
Case No. CV85–4544RJK (C. D. Cal.
1996), as well as the William
Wilberforce Trafficking Victims
Protection Reauthorization Act of 2008
(Pub. L. 110–457), which authorizes
post release services under certain
conditions to eligible children. All
programs must comply with the Flores
Settlement Agreement, Case No. CV85–
4544–RJK (C.D. Cal. 1996), pertinent
regulations and ORR policies and
procedures.
Christopher Beach,
Senior Grants Policy Specialist, Division of
Grants Policy, Office of Administration,
Administration for Children and Families.
[FR Doc. 2016–29326 Filed 12–6–16; 8:45 am]
BILLING CODE 4184–45–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–3274]
Posting Adverse Event Report Data
Associated With Conventional Foods,
Dietary Supplements, and Cosmetics
on the Internet; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or we) is
announcing the availability of data
extracted from adverse event reports
from January 2004 to the present
involving food (including food
additives, color additives, and dietary
supplements) and cosmetics regulated
by our Center for Food Safety and
Applied Nutrition (CFSAN). The data
files are being made publicly available
on FDA’s Web site to improve
transparency about adverse event
reports involving CFSAN-regulated
products and increase awareness about
reporting these adverse events to FDA.
FOR FURTHER INFORMATION CONTACT: Lyle
Canida, Center for Food Safety and
Applied Nutrition (HFS–014), Food and
Drug Administration, 5001 Campus Dr.,
College Park, MD 20740, 240–402–1817.
SUPPLEMENTARY INFORMATION:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
I. Background
We are announcing the availability of
data extracted from the CFSAN Adverse
Event Reporting System (CAERS) from
adverse event reports involving food
(including food additives, color
additives, and dietary supplements) and
cosmetics regulated by CFSAN that
were submitted to FDA from January
VerDate Sep<11>2014
17:54 Dec 06, 2016
Jkt 241001
2004 to the present. We will make these
data files available on a quarterly basis
on the FDA Web site at https://
www.fda.gov/Food/
ComplianceEnforcement/
ucm494015.htm. Each posting will
consist of adverse event report
information entered in CAERS for the
previous 3 months with a roughly one
month delay. The data files are provided
in ASCII format and include
information on the following topics (if
provided):
• Demographic (e.g., age, gender) and
administrative information regarding
the adverse event;
• Date of event;
• Product role (suspect or
concomitant);
• Reported brand/product name;
• Industry code/name;
• Reported symptom(s); and
• Outcome information.
CAERS with new information, the
number of reports for a given product
and the content of individual reports
may change over time. Furthermore,
even with respect to dietary
supplements, for which reporting of
serious adverse events is mandatory,
adverse events associated with any
product may be underreported. On the
other hand, in some instances there may
be duplicate reports in CAERS for the
same adverse event because multiple
people (such as an injured consumer
and a health care provider who treated
him or her) may have submitted reports.
Questions and answers (Q&As)
accompanying the data at our Web site
explain the data limitations, as well as
the reasons why we need complete
reporting.
What is CAERS?
The CAERS database collects reports
submitted by consumers, health
professionals, industry, and others
about adverse health events and product
complaints related to CFSAN-regulated
products. It includes voluntary reports
involving conventional foods, including
food additives and color additives, and
cosmetics, and both mandatory and
voluntary reports with respect to
adverse events involving dietary
supplements. Reports are mandatory for
dietary supplements used in the United
States in the case of a serious adverse
event that has resulted in death, a lifethreatening experience, inpatient
hospitalization, a persistent or
significant disability or incapacity, a
congenital anomaly or birth defect, or
that requires, based on reasonable
medical judgment, a medical or surgical
intervention to prevent one of those
outcomes (see 21 U.S.C. 379aa–1). In
such cases, dietary supplement
manufacturers, packers, and distributors
must notify FDA if they receive reports
about serious adverse events associated
with the use of the dietary supplement.
The goal of CAERS is to improve
consumer protection by providing FDA
with information from which we may be
able to quickly identify situations in
which the data provide a signal that a
particular product may be harmful and
should be investigated further.
However, we note that adverse event
reports about a particular product and
the total number of adverse event
reports for a product in the CAERS
database only reflect information
reported and do not represent any
conclusion by FDA about whether the
product actually caused the adverse
event(s). Because we constantly update
• We are making this information
available for the purpose of improving
transparency by providing the public,
including researchers and health care
professionals, with online access to
information from adverse event reports
about CFSAN-regulated products. This
information has previously been
available only through the process of
specific requests under the Freedom of
Information Act, 5 U.S.C. 552. In
addition, we believe that posting these
data may increase the number and
completeness of the adverse event
reports we receive. For the most part,
FDA does not have pre-market authority
over foods and cosmetics. As a result,
identifying through post-market
surveillance possible risks associated
with these products is critical.
PO 00000
Frm 00048
Fmt 4703
Sfmt 9990
Why is CFSAN posting these data on the
FDA Web site?
Where and when will data be posted?
• We will post CAERS data on a
quarterly basis on the FDA Web site at
https://www.fda.gov/Food/
ComplianceEnforcement/
ucm494015.htm. Each posting will
include adverse event reports entered in
CAERS for the previous 3 month period,
with a roughly one month delay. So for
example, if we post data files on the
CAERS Web page in February, the
information would consist of adverse
event reports entered (or revised) in
CAERS during the previous October
thru December time period. Data files
from the January thru March time
period would be posted in the following
May, and so on.
Dated: December 1, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–29277 Filed 12–6–16; 8:45 am]
BILLING CODE 4164–01–P
E:\FR\FM\07DEN1.SGM
07DEN1
Agencies
[Federal Register Volume 81, Number 235 (Wednesday, December 7, 2016)]
[Notices]
[Page 88244]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-29277]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-3274]
Posting Adverse Event Report Data Associated With Conventional
Foods, Dietary Supplements, and Cosmetics on the Internet; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing the
availability of data extracted from adverse event reports from January
2004 to the present involving food (including food additives, color
additives, and dietary supplements) and cosmetics regulated by our
Center for Food Safety and Applied Nutrition (CFSAN). The data files
are being made publicly available on FDA's Web site to improve
transparency about adverse event reports involving CFSAN-regulated
products and increase awareness about reporting these adverse events to
FDA.
FOR FURTHER INFORMATION CONTACT: Lyle Canida, Center for Food Safety
and Applied Nutrition (HFS-014), Food and Drug Administration, 5001
Campus Dr., College Park, MD 20740, 240-402-1817.
SUPPLEMENTARY INFORMATION:
I. Background
We are announcing the availability of data extracted from the CFSAN
Adverse Event Reporting System (CAERS) from adverse event reports
involving food (including food additives, color additives, and dietary
supplements) and cosmetics regulated by CFSAN that were submitted to
FDA from January 2004 to the present. We will make these data files
available on a quarterly basis on the FDA Web site at https://www.fda.gov/Food/ComplianceEnforcement/ucm494015.htm. Each posting will
consist of adverse event report information entered in CAERS for the
previous 3 months with a roughly one month delay. The data files are
provided in ASCII format and include information on the following
topics (if provided):
Demographic (e.g., age, gender) and administrative
information regarding the adverse event;
Date of event;
Product role (suspect or concomitant);
Reported brand/product name;
Industry code/name;
Reported symptom(s); and
Outcome information.
What is CAERS?
The CAERS database collects reports submitted by consumers, health
professionals, industry, and others about adverse health events and
product complaints related to CFSAN-regulated products. It includes
voluntary reports involving conventional foods, including food
additives and color additives, and cosmetics, and both mandatory and
voluntary reports with respect to adverse events involving dietary
supplements. Reports are mandatory for dietary supplements used in the
United States in the case of a serious adverse event that has resulted
in death, a life-threatening experience, inpatient hospitalization, a
persistent or significant disability or incapacity, a congenital
anomaly or birth defect, or that requires, based on reasonable medical
judgment, a medical or surgical intervention to prevent one of those
outcomes (see 21 U.S.C. 379aa-1). In such cases, dietary supplement
manufacturers, packers, and distributors must notify FDA if they
receive reports about serious adverse events associated with the use of
the dietary supplement.
The goal of CAERS is to improve consumer protection by providing
FDA with information from which we may be able to quickly identify
situations in which the data provide a signal that a particular product
may be harmful and should be investigated further.
However, we note that adverse event reports about a particular
product and the total number of adverse event reports for a product in
the CAERS database only reflect information reported and do not
represent any conclusion by FDA about whether the product actually
caused the adverse event(s). Because we constantly update CAERS with
new information, the number of reports for a given product and the
content of individual reports may change over time. Furthermore, even
with respect to dietary supplements, for which reporting of serious
adverse events is mandatory, adverse events associated with any product
may be underreported. On the other hand, in some instances there may be
duplicate reports in CAERS for the same adverse event because multiple
people (such as an injured consumer and a health care provider who
treated him or her) may have submitted reports. Questions and answers
(Q&As) accompanying the data at our Web site explain the data
limitations, as well as the reasons why we need complete reporting.
Why is CFSAN posting these data on the FDA Web site?
We are making this information available for the purpose
of improving transparency by providing the public, including
researchers and health care professionals, with online access to
information from adverse event reports about CFSAN-regulated products.
This information has previously been available only through the process
of specific requests under the Freedom of Information Act, 5 U.S.C.
552. In addition, we believe that posting these data may increase the
number and completeness of the adverse event reports we receive. For
the most part, FDA does not have pre-market authority over foods and
cosmetics. As a result, identifying through post-market surveillance
possible risks associated with these products is critical.
Where and when will data be posted?
We will post CAERS data on a quarterly basis on the FDA
Web site at https://www.fda.gov/Food/ComplianceEnforcement/ucm494015.htm. Each posting will include adverse event reports entered
in CAERS for the previous 3 month period, with a roughly one month
delay. So for example, if we post data files on the CAERS Web page in
February, the information would consist of adverse event reports
entered (or revised) in CAERS during the previous October thru December
time period. Data files from the January thru March time period would
be posted in the following May, and so on.
Dated: December 1, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-29277 Filed 12-6-16; 8:45 am]
BILLING CODE 4164-01-P